The results from a Phase III trial showed with weekly subcutaneous injections for 72 weeks, Teribone helps in decreasing the risk of developing new vertebral fracture by 78.6% compared to placebo treatment.
Teribone is a human parathyroid hormone preparation that facilitates bone formulation.